The US FDA’s standard for deciding whether pediatric studies “fairly respond” to a written request and whether exclusivity decisions stemming from those studies are entitled to judicial deference were the focus of oral arguments May 17 in Amgen Inc.'s appeal of the agency’s denial of pediatric exclusivity for its calcium-sensing receptor agonist Sensipar (cinacalcet).
Arguing before the US Court of Appeals for the District of Columbia Circuit, Amgen attorney Catherine Stetson, a partner at...




